{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:28:56Z","timestamp":1767421736620},"reference-count":76,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s336139","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T03:30:13Z","timestamp":1662607813000},"page":"913-927","source":"Crossref","is-referenced-by-count":17,"title":["A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application"],"prefix":"10.2147","volume":"Volume 18","author":[{"given":"Noah","family":"Becher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Swaminath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.3748\/wjg.v20.i12.3255","volume":"20","author":"Xu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature06005","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/35079107","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S2468-1253(16)30111-X","volume":"2","author":"Mirkov","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/jama.280.13.1128-JFD80009-2-1","volume":"280","author":"Nightingale","year":"1998","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"ref9","unstructured":"Administration USFaD. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. FDA. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed May 25, 2022."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1172\/JCI76369","volume":"125","author":"Proia","year":"2015","journal-title":"J Clin Invest"},{"key":"ref11","unstructured":"Biorender.com. \u201cNitric Oxide Synthesis 1\u201d, by BioRender.com; 2022. Available from: https:\/\/app.biorender.com\/biorender-templates. Accessed August 25, 2022."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1126\/science.1139221","volume":"316","author":"Pappu","year":"2007","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1161\/CIRCRESAHA.107.165845","volume":"102","author":"Venkataraman","year":"2008","journal-title":"Circ Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1084\/jem.20091619","volume":"207","author":"Pham","year":"2010","journal-title":"J Exp Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nri1650","volume":"5","author":"Rosen","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.tem.2007.07.005","volume":"18","author":"Alvarez","year":"2007","journal-title":"Trends Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/pr.110.003111","volume":"62","author":"Chun","year":"2010","journal-title":"Pharmacol Rev"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","volume":"20","author":"Argollo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molmed.2017.02.002","volume":"23","author":"Nielsen","year":"2017","journal-title":"Trends Mol Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.bbalip.2008.07.003","volume":"1781","author":"Hla","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.advenzreg.2009.10.024","volume":"50","author":"Serra","year":"2010","journal-title":"Adv Enzyme Regul"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature24053","volume":"550","author":"Vu","year":"2017","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bbrc.2007.03.123","volume":"357","author":"Ito","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.celrep.2012.09.021","volume":"2","author":"Mendoza","year":"2012","journal-title":"Cell Rep"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/intimm\/dxz037","volume":"31","author":"Obinata","year":"2019","journal-title":"Int Immunol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1084\/jem.20092210","volume":"207","author":"Allende","year":"2010","journal-title":"J Exp Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e9277","DOI":"10.1371\/journal.pone.0009277","volume":"5","author":"Pereira","year":"2010","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1126\/science.1113640","volume":"309","author":"Schwab","year":"2005","journal-title":"Science"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3389\/fimmu.2019.01168","volume":"10","author":"Hampton","year":"2019","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","volume":"115","author":"Brinkmann","year":"2007","journal-title":"Pharmacol Ther"},{"key":"ref32","unstructured":"Biorender.com. \u201cStimulated T Cells Migrate Out of Lymph Nodes and Enter Inflamed Tissue\u201d, by BioRender.com; 2022. Available from: https:\/\/app.biorender.com\/biorender-templates. Accessed August 25, 2022."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature02284","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"21453","DOI":"10.1074\/jbc.C200176200","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4103\/0976-500X.77118","volume":"2","author":"Sharma","year":"2011","journal-title":"J Pharmacol Pharmacother"},{"key":"ref37","unstructured":"Administration USFaD. FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gilenya-treat-multiple-sclerosis-pediatric-patients. Accessed May 28, 2022."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","volume":"4","author":"Brinkmann","year":"2004","journal-title":"Am J Transplant"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1126\/science.1070238","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.4049\/jimmunol.175.11.7151","volume":"175","author":"Singer","year":"2005","journal-title":"J Immunol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1124\/mol.115.100222","volume":"89","author":"Sanna","year":"2016","journal-title":"Mol Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"ref43","unstructured":"Administration USFaD. Center for drug evaluation and research. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022527Orig1s000medr.pdf. Accessed July 28, 2022."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13311-017-0565-4","volume":"14","author":"Chaudhry","year":"2017","journal-title":"Neurotherapeutics"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40265-019-01140-x","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40263-020-00771-z","volume":"34","author":"Scott","year":"2020","journal-title":"CNS Drugs"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bph.13476","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","volume":"15","author":"Sandborn","year":"2021","journal-title":"J Crohns Colitis"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref53","unstructured":"U.S. National Library of Medicine NIoH. Induction Study #2 of oral ozanimod as induction therapy for moderately to severely active crohn\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03440385. Accessed May 28, 2022."},{"key":"ref54","unstructured":"U.S. National Library of Medicine NIoH. Induction Study #1 of oral ozanimod as induction therapy for moderately to severely active crohn\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03440372. Accessed May 28, 2022."},{"key":"ref55","unstructured":"U.S. National Library of Medicine NIoH. An extension study of oral ozanimod for moderately to severely active crohn\u2019s disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03467958. Accessed May 28, 2022."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-021-01523-z","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref57","unstructured":"U.S. National Library of Medicine NIoH. A phase 3 study of etrasimod in subjects with moderately to severely active ulcerative colitis. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04176588. Accessed May 28, 2022."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amsu.2016.07.019","volume":"11","author":"Antoniou","year":"2016","journal-title":"Ann Med Surg"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"G135","DOI":"10.1152\/ajpgi.90462.2008","volume":"296","author":"Ostanin","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/jcph.887","volume":"57","author":"Tran","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/cpdd.383","volume":"7","author":"Tran","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/1352458513500551","volume":"20","author":"Francis","year":"2014","journal-title":"Mult Scler"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1124\/dmd.120.000220","volume":"49","author":"Surapaneni","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1007\/s12325-020-01473-0","volume":"37","author":"Tran","year":"2020","journal-title":"Adv Ther"},{"key":"ref65","unstructured":"Squibb BM. Zeposia \u00ae (ozanimod) Full Prescribing Information. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_zeposia.pdf. Accessed August 8, 2022."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/cpdd.409","volume":"7","author":"Tran","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/gutjnl-2018-316702","volume":"68","author":"Jairath","year":"2019","journal-title":"Gut"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jval.2017.02.005","volume":"20","author":"Null","year":"2017","journal-title":"Value Health"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","volume":"14","author":"Shah","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/01.MIB.0000437986.00190.71","volume":"20","author":"Mosli","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cgh.2013.07.022","volume":"12","author":"Peyrin-Biroulet","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref74","unstructured":"Squibb BM. U.S. food and drug administration approves Bristol Myers squibb\u2019s Zeposia\u00ae (ozanimod), an oral treatment for adults with moderately to severely active ulcerative colitis. Available from: https:\/\/news.bms.com\/news\/details\/2021\/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Zeposia-ozanimod-an-Oral-Treatment-for-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis1\/default.aspx. Accessed May 27, 2022."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"ref76","unstructured":"U.S. National Library of Medicine NIoH. A study of efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (VEGA). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03662542. Accessed July 28, 2022."}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=83730","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=83730","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T03:30:18Z","timestamp":1662607818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/a-literature-review-of-ozanimod-therapy-in-inflammatory-bowel-disease--peer-reviewed-fulltext-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":76,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s336139","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}